SCHEMBL4618290

SCHEMBL4618290

CC(=O)OCc1ccccc1C#N

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
RAB9A P51151 3/20 0.56
NPC1 O15118 1/20 0.56
TSHR P16473 1/20 0.56
TDP1 Q9NUW8 2/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
KDM4E B2RXH2 1/20 0.53
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
FFAR1 O14842 1/20 0.49
GALR3 O60755 1/20 0.45
HTT P42858 1/20 0.44
MAOB P27338 1/20 0.43
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALKBH1 Q13686 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19765228 0.85 ALDH1A1 (0.54) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL5932420 0.84 ALDH1A1 (0.55) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL442437 0.84 ALDH1A1 (0.52) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL30163264 0.84 ALDH1A1 (0.55) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL1232755 0.84 ALDH1A1 (0.45) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL6523075 0.84 ALDH1A1 (0.51) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL30061341 0.83 ALDH1A1 (0.44) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL13069883 0.83 ALDH1A1 (0.53) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL27433027 0.83 ALDH1A1 (0.50) ALDH1A1RAB9ANPC1TSHRTDP1
SCHEMBL287344 0.83 ALDH1A1 (0.57) ALDH1A1RAB9ANPC1TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946058-A Preparation method of 3-isochromone 上海试四化学品有限公司 2024-04-30 CN disclosed
EP-1893766-A1 CHEMOENZYMATIC PROCESS FOR THE SYNTHESIS OF ESCITALOPRAM Adorkem Technology SpA (IT) 2008-03-05 EP disclosed
US-20070161681-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER INC. (US) 2007-07-12 US disclosed
US-7183293-B2 Ether derivatives useful as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-02-27 US disclosed
WO-2006136521-A1 CHEMOENZYMATIC PROCESS FOR THE SYNTHESIS OF ESCITALOPRAM ADORKEM TECHNOLOGY SPA (IT) 2006-12-28 WO disclosed
EP-1733042-A1 CHEMO-ENZYMATIC PROCESS FOR PREPARING ESCITALOPRAM Adorkem Technology SpA (IT) 2006-12-20 EP disclosed
WO-2005098018-A1 CHEMO-ENZYMATIC PROCESS FOR PREPARING ESCITALOPRAM ADORKEM TECHNOLOGY SPA (IT) 2005-10-20 WO disclosed
US-4091010-A Process for the preparation of cyanohydrin esters SUNTECH, INC. (US) 1978-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161681-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PDE4A, PDE4B, PDE4D ALDH1A1 424/4885RAB9A 993/4885NPC1 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.